Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents.

Qi Yan,Yujie Wang,Wei Zhang,Yingxia Li
DOI: https://doi.org/10.3390/md14050085
2016-01-01
Marine Drugs
Abstract:A conformational restriction strategy was used to design and synthesize nine TZT-1027 analogues. 3-Aryl-azetidine moiety was used to replace phenylethyl group of TZT-1027 at the C-terminus. These analogues exhibited moderate to excellent antiproliferative activities, and the most potent compound 1a showed IC50 values of 2.2 nM against A549 and 2.1 nM against HCT116 cell lines, respectively. However, 1a could not achieve effective inhibition at all the dose levels in the A549 xenograft model (up to 5 mg/kg, injection, once a day), which is only 16%-35% inhibition at the end of the experiment.
What problem does this paper attempt to address?